People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

Hemophilia A, also known as classic hemophilia or factor VIII deficiency, is a bleeding disorder. It occurs when certain proteins are missing in the blood, causing people to bleed and bruise easily.

Factor replacement therapy is the primary treatment for people with hemophilia A. But a doctor may also prescribe a combination of other medications and physical therapy. Hemophilia A is a severe ...

Please provide your email address to receive an email when new articles are posted on . The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...

Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...

There are several lab tests for hemophilia. However, the main tests detect the clotting activity of factors VIII and IX, which are proteins in the blood. Hemophilia is a bleeding disorder in which an ...

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF XTEN Fusion Protein], a first-in-class, ...